Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet prostaglandin E1 hyposensitivity in schizophrenia: decrease in cyclic AMP formation and in inhibitory

H Kaiya1, M Ofuji, M Nozaki

  • 1Department of Neurology and Psychiatry, Gifu University School of Medicine, Japan.

Psychopharmacology Bulletin
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deficit of state-dependent risk attitude modulation in gambling disorder.

Translational psychiatry·2017
Same author

Central injection of urocortin-3 but not corticotrophin-releasing hormone influences the ghrelin/GHS-R1a system of the proventriculus and brain in chicks.

Domestic animal endocrinology·2014
Same author

An issue to keep in mind regarding specific suicide prevention measures: focussing on bipolar disorder.

The West Indian medical journal·2013
Same author

Meta-analysis of genome-wide association studies for panic disorder in the Japanese population.

Translational psychiatry·2012
Same author

Replication and meta-analysis of TMEM132D gene variants in panic disorder.

Translational psychiatry·2012
Same author

The role of GABAergic system on the inhibitory effect of ghrelin on food intake in neonatal chicks.

Neuroscience letters·2012

Platelets from schizophrenic patients show reduced cyclic adenosine monophosphate (cAMP) formation and hyposensitivity to prostaglandin E1 (PGE1). This suggests aberrant adenylate cyclase activity contributes to platelet dysfunction in schizophrenia.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Psychiatry

Background:

  • Schizophrenia is a complex psychiatric disorder with potential links to cellular signaling pathways.
  • Platelet function and cyclic adenosine monophosphate (cAMP) signaling have been implicated in various neurological conditions.

Purpose of the Study:

  • To investigate cyclic adenosine monophosphate (cAMP) formation in platelets of schizophrenic patients.
  • To assess the inhibitory effects of prostaglandin E1 (PGE1) and forskolin on platelet aggregation response (PAR) in schizophrenia.
  • To explore the relationship between cAMP levels and platelet response to inhibitors in schizophrenic patients.

Main Methods:

  • Washed platelets from 35 schizophrenic patients and 34 normal controls were used.
  • Cyclic adenosine monophosphate (cAMP) formation was measured following stimulation with prostaglandin E1 (PGE1) or forskolin.

Related Experiment Videos

  • The inhibitory effects of PGE1 and forskolin on adenosine diphosphate (ADP)-induced platelet aggregation response (PAR) were assessed.

    • Main Results:

    • Both PGE1- and forskolin-stimulated cAMP formation were significantly decreased in platelets from schizophrenic patients compared to controls.
    • Prostaglandin E1 (PGE1) inhibition of platelet aggregation response (PAR) was significantly reduced in schizophrenic patients.
    • Forskolin's inhibitory effect on PAR was not significantly different between schizophrenic patients and normal controls.

    Conclusions:

    • Platelet hyposensitivity to prostaglandin E1 (PGE1) in schizophrenia is partly due to aberrant adenylate cyclase (AC) activity.
    • Other factors related to platelet aggregation response (PAR) also contribute to the observed hyposensitivity.
    • These findings highlight potential alterations in platelet signaling pathways in schizophrenia.